Omega-3, Inflammation in ADHD With AI

Omega-3 Fatty Acids, Inflammation and Attention Deficit Hyperactivity Disorder (ADHD) With AI (OmInADHDAI)- A Double-blind Randomized Controlled Trial of High Dose Omega-3 Fatty Acids in Children With ADHD With High Inflammation Status

This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in children with attention deficit hyperactivity disorder (ADHD).

This is a 12 week study to investigate the effects of omega-3 PUFAs in children (6-12 years-old) with ADHD.

The primary outcome will be the clinical symptoms The secondary outcomes will be inflammatory biomarkers, cognitive function and physiological markers such as heart-rate variability.

Inclusion Criteria:

• Diagnosis of ADHD (DSM-5) made by a child and adolescent psychiatrist.
• Age range: 6-12 years old at the time of enrollment.
• SNAP-IV (Mandarin Chinese Version):

Inattention subscale score > 12 or Hyperactivity/impulsivity subscale score > 12 or Total score > 24

• Drug-naïve or no ADHD medication use in the past 6 months.
• Signed informed consent required.

Exclusion Criteria:

• Intelligence quotient <80
• Comorbid other psychiatric disorders, such as autism spectrum disorder, anxiety disorder, conduct disorder, schizophrenia, mood disorder
• Comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders
• Currently using omega-3 supplements
• Allergy to omega-3